NAD+ / NAD+ Precursors

WHAT IT IS

NAD+ is a coenzyme built from nicotinamide and adenine dinucleotide components. Cells use it constantly as the carrier that shuttles electrons through the reactions that convert food into usable energy.

It is not a peptide. Peptides are short chains of amino acids. NAD+ belongs to an entirely different chemical family, and describing it as a peptide is inaccurate even when it appears alongside peptides in a reference library.

In the body, NAD+ participates in mitochondrial energy production, supports enzymes involved in DNA repair, and acts as a required substrate for signaling enzymes such as sirtuins and PARPs.

NAD+, NADH, NMN AND NR: THE DIFFERENCES THAT MATTER

These names are used interchangeably in marketing, but they describe different molecules with different roles.

• NAD+ is the oxidized form of the coenzyme, the version ready to accept electrons during metabolism.
• NADH is the reduced form, the version already carrying electrons. Cells continually cycle between the two, and the ratio between them is itself a metabolic signal.
• NMN, nicotinamide mononucleotide, is a precursor. Cells can convert it into NAD+ through a defined enzymatic step.
• NR, nicotinamide riboside, is a different precursor that enters the same salvage pathway and is the form most often studied in published human trials.
• Niacin and nicotinamide, familiar B3 vitamin forms, also feed NAD+ production and have long-standing nutritional research behind them.

The practical point is that taking a precursor is not the same as taking NAD+, and a change in one pool does not automatically translate into a change in the biological processes people care about.

WHAT RESEARCHERS ARE STUDYING IT FOR

• Whether NAD+ levels decline with age in specific human tissues and what that decline means
• Whether raising NAD+-related biomarkers changes measurable health outcomes
• Mitochondrial function, metabolic health and insulin sensitivity
• Muscle function, physical performance and recovery in older adults
• Neurological and cognitive research applications
• Cardiovascular and kidney research contexts

ORAL PRECURSORS VERSUS INJECTABLE OR INTRAVENOUS NAD+

These are not interchangeable, and they should not be discussed as though they were.

Oral NR and NMN are the forms with the most published, placebo-controlled human trial data. Several of those trials report that blood NAD+-related metabolites rise measurably and that short-term tolerability is generally acceptable in the populations studied.

Injected or infused NAD+ is a different situation. It is used in some clinic settings, but published randomized controlled evidence for general wellness, energy or anti-aging outcomes is far thinner than the volume of marketing would suggest, and infusion carries route-specific considerations that oral supplementation does not.

In the United States, oral precursors sold as dietary supplements are regulated differently from prescription drugs. A supplement does not undergo the FDA efficacy review that an approved medication does.

WHAT THE EVIDENCE CURRENTLY SUGGESTS

The underlying biology is not in question. NAD+ is genuinely essential, its role in metabolism is textbook science, and severe deficiency of its dietary precursors causes well-characterized disease.

Human supplementation trials tell a narrower story. Multiple randomized studies of NR, and a smaller set for NMN, show that these compounds can raise NAD+-related blood biomarkers.

What those same trials have generally not shown is consistent, clinically meaningful improvement in energy, cognition, body composition, athletic performance or longevity. Results across outcome measures have been mixed, modest or neutral.

That gap between mechanism and outcome is the single most important thing to understand about this category.